Prognostic significance of long non-coding RNAs in clear cell renal cell carcinoma

Abstract

Background:Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer in adults, and patients with advanced ccRCC have a 5-year survival rate of <30%. The poor prognosis of ccRCC is closely related to its lacking of potential therapeutic and prognostic biomarkers. This meta-analysis aimed to elucidate the precise prognostic value of long non-coding RNAs (lncRNAs) in patients with ccRCC.Methods:A literature search was performed in related databases up to January 31, 2019. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated to explore the relationship between special lncRNAs expression and survival in patients with ccRCC.Results:After literature researching, a total of 16 studies, including 13 lncRNAs were identified. The data from studies that investigated the association between lncRNA expression and survival outcomes in patients with ccRCC were extracted. Results revealed that lncRNAs expression was significantly associated with poor overall survival (OS) outcome in patients with ccRCC (HR = 1.71, 95%CI = 1.40–2.01 in up-regulated subgroup; HR = 0.53, 95% CI = 0.25–0.80 in down-regulated subgroup). The overexpression of PVT1 was significantly associated with poor OS in ccRCC (HR = 1.51, 95% CI = 1.02–2.00). Meanwhile, up-regulation of LUCAT1 was significantly related to worse OS in ccRCC patients (HR = 1.51, 95% CI = 1.01–2.00).Conclusions:These results suggest that lncRNAs could be used to predict unfavorable prognosis and function as potential prognostic biomarkers in ccRCC.

Long noncoding RNA TUG1 promotes cell proliferation and migration of renal cell carcinoma via regulation of YAP

“…24 In different types of cancers, the expression level and carcinogenic role of TUG1 are variable. 11 Using siRNA knockdown, our functional study demonstrated that TUG1 could promote both cell proliferation and cell migration in RCC cells, which was consistent with previous findings. 12 However, overexpression of TUG1 was frequently observed in many other cancer types, such as esophageal squamous cell carcinoma, osteosarcoma, and colorectal cancer.…”

“…8,9 By screening genes controlled by taurine in retinal cells, taurine-upregulated gene 1 (TUG1) was identified as a novel lncRNA, which is upregulated by taurine and is essential for cell differentiation. [11][12][13] However, the underlying mechanisms of TUG1 in driving RCC progression are unclear. [11][12][13] However, the underlying mechanisms of TUG1 in driving RCC progression are unclear.…”

“…10 Later studies show that TUG1 is overexpressed in a variety of cancer types containing RCC. [11][12][13] However, the underlying mechanisms of TUG1 in driving RCC progression are unclear.…”

Identification of cancer‐related potential biomarkers based on lncRNA–pseudogene–mRNA competitive networks

“…For example, candidate KIRP‐related ceRNAs contained 15 lncRNAs and 10 pseudogenes. For the 15 lncRNAs, TUG1 was confirmed to be associated with renal cell carcinoma and nine of the other lncRNAs were enriched in cancer‐related function. Moreover, lncRNA SNHG16 was related to BLCA.…”

“…LncRNAs TUG1, OIP5-AS1, HNRNPU-AS1, LINC00641, HCG18, CASC7 and FGD5-AS1 acted as biomarkers for four cancer types. Among them, TUG1 is a well-known cancer-related lncRNA that plays an important role in many cancers [30,[38][39][40] and OIP5-AS1 was reported to be associated with multiple myeloma by Yang et al [41]. Xin et al [42] also showed that HNRNPU-AS1derived miR-205-5p modulated human endometrial cancer by targeting PTEN.…”